NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UnitedHealth Group Incorporated (NYSE: UNH) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UnitedHealth you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/unitedhealth-group-incorporated. Investors have until July 7, 2025, to ask the ...

Investors have until June 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased BigBear.ai securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned Priewe v. BigBear.ai Holdings, Inc., et al., No. 25-cv-00623. Why was BigBear.ai Sued for Securities Fraud? BigBear.ai is an AI-driven technology solutions company t ...

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation of risks associated with its loan portfolio [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Delaware, captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326, with investors having until May 16, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Bancorp stock [2]. Group 2: Company Overview - Bancorp is a financial holding company involved in institutional banking, commercial real estate bridge lending, small business lending, and commercial fleet leasing, with its REBL loans primarily collateralized by apartment buildings [3]. Group 3: Allegations of Misrepresentation - The complaint alleges that Bancorp misrepresented the significant risk of default or loss on its REBL loan portfolio and that its credit loss methodology was inadequate [4]. - It is claimed that Bancorp misrepresented the effectiveness of its internal controls over financial reporting, which contained at least one material weakness [4]. Group 4: Stock Performance and Impact - Following a report from Culper Research on March 21, 2024, which highlighted misrepresentation of risks, Bancorp's stock price fell over 10%, from $36.04 to $32.12 [5]. - On October 24, 2024, Bancorp reported a net income of $51.5 million, leading to a 14% decline in stock price from $54.96 to $47.01 due to increased credit losses [6]. - On March 4, 2025, Bancorp disclosed inappropriate filing of its Annual Report, causing a 4.4% drop in stock price from $53.59 to $51.25 [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding Medicaid cost trends and premium negotiations [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance Health common stock between April 18, 2024, and October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, while in reality, the acuity and utilization of Medicaid members were increasing significantly [5]. - The lawsuit suggests that the members being removed from Medicaid were healthier than those who remained, which was not accounted for in Elevance's rate negotiations or financial forecasts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

NEW YORK, May 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bitfarms Ltd. (NASDAQ: BITF) between March 21, 2023 and December 9, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2025.So What: If you purchased Bitfarms securities during the Class Period you may b ...

Group 1 - Johnson Fistel, PLLP is investigating Autodesk, Inc. to determine if there have been violations of federal and/or state laws by its executive officers or associated parties [1][2] - The investigation focuses on Autodesk's corporate governance practices and whether they comply with established legal precedents regarding fiduciary duties [2] - Johnson Fistel is a nationally recognized law firm specializing in shareholder rights, representing both individual and institutional investors in securities class action lawsuits [3] Group 2 - In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, highlighting its effectiveness in advocating for investors [4] - The firm has recovered approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [4]

Core Viewpoint - A lawsuit has been filed against UnitedHealth Group Incorporated and certain senior executives for potential violations of federal securities laws, alleging a corporate strategy of improperly denying health coverage to increase profits [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Faller v. UnitedHealth Group Incorporated, et al., No. 25-cv-03799 [2]. - Investors have until July 7, 2025, to request to be appointed to lead the case [2]. Group 2: Allegations and Corporate Strategy - The complaint claims that UnitedHealth has engaged in a long-term strategy of denying health coverage, which has led to regulatory scrutiny and public backlash [3]. - The strategy reportedly contributed to the death of the CEO of UnitedHealthcare in December 2024, prompting the company to ease its denial of health insurance claims while maintaining previous financial guidance [3]. Group 3: Stock Performance and Financial Guidance - On April 17, 2025, UnitedHealth reduced its full-year 2025 financial guidance, citing heightened care activity in its Medicare Advantage business, leading to a stock price decline of over 22%, from $585.04 to $454.11 per share [4]. - Following the unexpected departure of CEO Andrew Witty on May 13, 2025, the stock price fell more than 10% during trading on the same day [5].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  EchoStar Corporation (“EchoStar” or the “Company”) (NASDAQ: SATS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether EchoStar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 12 ...

Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in its stock price [1][3]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, missing consensus estimates by $0.05 [3]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, following the earnings announcement [3]. Management Commentary - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain during the first quarter, attributed to customer manufacturing start-up challenges [3].

Core Viewpoint - Northrop Grumman Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which included significant charges related to its B-21 bomber program [1][3]. Financial Performance - Northrop Grumman reported revenue of $9.47 billion for Q1 2025, reflecting a 7% year-over-year decline and falling short of consensus estimates by $480 million [3]. - The company incurred a pretax charge of $477 million associated with manufacturing updates for the B-21 bomber program, attributed to inflationary factors by the CEO [3]. - Following the announcement of these results, Northrop Grumman's stock price dropped by $67.25 per share, or 12.66%, closing at $464.08 per share on April 22, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful practices by Northrop Grumman and its officers/directors [1].